and metal--and also suppressed biofilm formation in a study reported in Nature Biotechnology. But that's not All the team implanted medical-grade tubing
since the earliest days of endoscopy,"says Timo Cuntz, a member of the Project Group for Automation in Medicine and Biotechnology PAMB in Mannheim, a part of the Fraunhofer Institute for Manufacturing Engineering and Automation IPA.
'A new method developed at the Centre for Plant Biotechnology and Genomics (CBGP UPM-INIA) has shown that by the contact of a plant with a strain of the Colletotrichum tofieldiae microorganism previously isolated this plant can increase the number size
pageac=patente. jsp&idpatente=812) and there is an exclusive commercial patent license agreement with Plant Response Biotech S l. a spin-off company from the Universidad Politécnica de Madrid created in 2008 that focuses its work on the development
and biotechnology to precisely manipulate small volumes of fluids for use in applications such as enzymatic or DNA analysis pathogen detection clinical diagnostic testing and synthetic chemistry.
For the past 20 years microfluidics has been considered a boon for fields like biotechnology and engineering but has yet to be standardized
Our idea is to create a biosensor that can transmit electrical signals through the membrane said María José Retamal a Ph d. student at Pontificia Universidad Católica de Chile and first author of the paper.
After developing Cellsqueeze at MIT, Sharei co-founded SQZ Biotech in 2013 to further develop and commercialize the platform.
Meanwhile, SQZ Biotech aims to reduce the footprint of its device, which could potentially lower the time
Gilead sciences, Inc.;the Howard Hughes Medical Institute; the Department of Dermatology; and the Yale Comprehensive Cancer Center.
biotechs race to develop acute radiation drugs Since the nuclear crisis at the Fukushima Daiichi power station,
Now, however, several small biotech companies are racing to develop the first approved therapy for ARS,
#Where the bio-rubber meets the road My posts about biotechnology as it relates to agriculture tend to draw impassioned naysayers,
but surely here's a biotech application with which they can relate: a renewable fermentation process that seeks to act as a partial replacement for the an oil-based processes that goes into making synthetic rubber.
Biotech company Genencor, which is a division of Danisco, is more than one year into testing the commercial applications for
The work was published in Nature Biotechnology this week. And just last week Technology Review reported that Roche backed off its hostile takeover bid for Illumina,
Hitachi is also working on nanopore technology as are startups like Electronic Biosciences. Deamer says the idea of nanopore sequencing occurred to him in 1989 just three years after the first automated DNA sequencers were introduced.
which is manufactured by the American pharmaceutical company Amgen, have already been submitted to drugs regulators in Europe and the USA.
which is manufactured by the American pharmaceutical company Amgen, have already been submitted to drugs regulators in Europe and the USA.
-and nanomechanical biosensors for quite a while now and can say that no one has been able to introduce a simple and scalable technology for parallel monitoring that would be ready to use outside a laboratory,
-and nanomechanical biosensors for quite a while now and can say that no one has been able to introduce a simple and scalable technology for parallel monitoring that would be ready to use outside a laboratory,
-and nanomechanical biosensors for quite a while now and can say that no one has been able to introduce a simple and scalable technology for parallel monitoring that would be ready to use outside a laboratory,
both have an extensive background in biotechnology. At age 18, Erik Gatenholm started his first medical device company, manufacturing meniscus implants and other implants, such surgical meshes for ventral hernia repairs and wound dressings.
but also pave the way for more complex optical fiber structures that are able to host a variety of applications for industries ranging from telecommunications and aerospace to biotechnologies and more."
and Tong Wang, the other lead co-author of the paper and who also works with Li in the Biosciences department of Brookhaven.
who is also director of the NSF-NASA Center for Chemical Evolution and associate director of the Parker H. Petit Institute of Bioengineering and Bioscience,
Emiliana De Santis, who is developing the standard in NPL's Biotechnology Group, said:""Our ability to exploit self-assembly processes allows us to enable
-and nanomechanical biosensors for quite a while now and can say that no one has been able to introduce a simple and scalable technology for parallel monitoring that would be ready to use outside a laboratory.
biotechnology and nanobiotechnology for applications including targeted drug delivery. Chirality of an object is its property that allows it to be non-superimposable with its mirror image.
#Polymer Nanobrushes Grab Selected Bacteria for Pathogen Detection A Texas A&m Agrilife Research engineer and a Florida colleague have developed a biosensor that can detect listeria bacterial contamination within two
The biosensor she is working on is still in the prototype stage of development, but in a few years she envisions a hand-held device that will require hardly any training to use.
"The selection process the polymers use to select for specific bacteria in the listeria biosensor is very similar to the squid's cilia.
"Currently, the listeria biosensor is about the size of a postage stamp, with two wires leading to two etched conductive areas.
Also in the works is a disposable paper-based biosensor that can be disposed of after one use.
which also has an area of`Biotechnology and Drug Research of Biomedical engineering, Diagnosis and Treatment Equipment.
Earlier this month, MIT spinout Microchips Biotech partnered with a pharmaceutical giant to commercialize its wirelessly controlled, implantable,
Invented by Microchips Biotech cofounders Michael Cima, the David H. Koch Professor of Engineering, and Robert Langer, the David H. Koch Institute Professor, the microchips consist of hundreds of pinhead-sized reservoirs,
and osteoporosis. Now Microchips Biotech will begin co-developing microchips with Teva Pharmaceutical, the world largest producer of generic drugs,
Apart from providing convenience, Microchips Biotech says these microchips could also improve medication-prescription adherence a surprisingly costly issue in the United states. A 2012 report published in the Annals of Internal medicine estimated that Americans who don stick to prescriptions rack up $100 billion
Microchips Biotech will continue work on its flagship product, a birth-control microchip, backed by the Bill and Melinda Gates Foundation,
Cima, who now serves on the Microchips Biotech board of directors with Langer, sees this hormone-releasing microchip as one of the first implantable rtificial organsbecause it acts as a gland. lot of the therapies are trying to chemically trick the endocrine systems Cima says. e are doing that with this artificial organ we created.
For years, the technology underwent rigorous research and development at Microchips Biotech. But in 2011, Langer and Cima,
MEMS innovations Microchips Biotech made several innovations in the microelectromechanical systems (MEMS) manufacturing process to ensure the microchips could be commercialized.
To do so, Microchips Biotech modified a cold-welding ongue and grooveprocess. This meant depositing a soft,
Aurasense, Inc.,a biotechnology company that licensed the Nanoflare technology from Northwestern University, and EMD-Millipore, another biotech company, have commercialized Nanoflares.
There are now more than 1, 700 commercial forms of Nanoflares sold under the Smartflare? name in more than 230 countries.
biotechnology and instrumentation expertise to develop a portable, autonomous device that analyzes trace elements. The highly miniaturized microbial analysis machine,
#Novel Synthetic Biosensor Glows in Response to Conditions that Mimic TB Infection Robert Abramovitch, an MSU microbiologist,
By using a synthetic biosensor that glows green in response to conditions that mimic TB infection,
Lead researcher Aydogan Ozcan, Howard Hughes Medical Institute chancellor professor at UCLA, sat down with Bioscience Technology to talk about this advancement and its implications for resource-poor labs,
Kai Liu. he ability to detect even smaller amounts of chemical and biological molecules could be helpful with biosensors that are used to detect cancer,
Ph d.,a postdoctoral fellow at the University Of Virginia School of medicine, told Bioscience Technology. ecently, we have seen that the areas that are surrounding the brain are full of immune cells, even in normal conditions,
Louveau told Bioscience Technology. he first question we are addressing is confirming that this structure exists in humans
However, fewer companies have worked on vaccines and drugs for the MERS virus, according to Reuters. Small biotech companies such as Greffex,
Earlier this month, MIT spinout Microchips Biotech partnered with a pharmaceutical giant to commercialize its wirelessly controlled, implantable,
Invented by Microchips Biotech cofounders Michael Cima, the David H. Koch Professor of Engineering, and Robert Langer, the David H. Koch Institute Professor, the microchips consist of hundreds of pinhead-sized reservoirs,
and osteoporosis. Now Microchips Biotech will begin co-developing microchips with Teva Pharmaceutical, the world largest producer of generic drugs,
Apart from providing convenience, Microchips Biotech said these microchips could also improve medication-prescription adherence a surprisingly costly issue in the United states. A 2012 report published in the Annals of Internal medicine estimated that Americans who don stick to prescriptions rack up $100 billion
Microchips Biotech will continue work on its flagship product, a birth-control microchip, backed by the Bill and Melinda Gates Foundation,
Cima, who now serves on the Microchips Biotech board of directors with Langer, sees this hormone-releasing microchip as one of the first implantable rtificial organsbecause it acts as a gland. lot of the therapies are trying to chemically trick the endocrine systems Cima said. e are doing that with this artificial organ we created.
For years, the technology underwent rigorous research and development at Microchips Biotech. But in 2011, Langer and Cima,
MEMS innovations Microchips Biotech made several innovations in the microelectromechanical systems (MEMS) manufacturing process to ensure the microchips could be commercialized.
To do so, Microchips Biotech modified a cold-welding ongue and grooveprocess. This meant depositing a soft,
#New Single-use Harvesting Technology for High Cell Density Cultures Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has introduced Sartoclear Dynamics,
Sartorius Stedim Biotech has developed now this robust technology for biotech applications. Specially designed for cgmp processing
which is attractive for newcomers from emerging biotech markets. The ready-to-use clarification system enables harvesting of high cell density cultures up to 2, 000 liters 0
Anstie told Bioscience Technology. ather than sniffing out a variety of smells as a dog would,
Anstie told Bioscience Technology, ther conditions, although they have a clear molecular signature in the breath may be masked by the general complexity involved in getting a good repeatable sample.
or biosensors, in bacteria that are placed then in the gut, this paper stands out from the crowd by first engineering a member of the Bacteroides genus,
a clinical stage biopharmaceutical company which owns the core T-cell receptor technology and funded the study.
one of the authors of the study and Professor of Biotechnology and Therapeutics at the Graduate school of Pharmaceutical Sciences at Osaka University. ecause the new patch is so easy to use,
the research team included Professor Vladimir Tsukruk from the Georgia Tech School of Materials science and engineering and Rajesh Naik, Biotechnology Lead and Tech Advisor of the Nanostructured and Biological Materials Branch
and by Georgia Tech Renewable Bioproducts Institute Fellowship. The content is solely the responsibility of the authors
#State Deficits to Shrink & Taxes Drop-Good News for Biotech Forecasters at the National Conference of State Legislatures2011 Legislative Summit expect a dramatic reduction of state deficits in the coming years,
Unfortunately these corporate tax cuts do not provide much-needed capital to small biotech companies because their lack of profits makes tax benefits unredeemable.
Most emerging biotech companies with promising scientific innovation are small, research-intensive and not yet profitable because they do not have approved an FDA product on the market.
Biotech start-ups generally struggle to raise capital to finance their research, and BIO advocates two important policies that enable them to continue critical R&d of advancements and breakthroughs.
The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.
I have noticed a promising trend the rise of open source drug R&d consortia that include large biotech
and biotech companies to develop better treatments most recently with Shire around rare diseases. These alliances leverage Boston Children research expertise and companiesdevelopment and commercialization capabilities.
generating creative initiatives from universities, tech transfer organizations, government and biotechs. BIO-X is an open innovation vehicle run by Uppsala BIO.
and small biotechs, offering to support their ideas through to proof of principle. or the proposals selected,
#Biotechnology Helps Meet Consumer Demand for Earth-Friendly Products Industrial biotechnology has its roots in cleaning up environmental hazards.
Today, biotechnology enables manufacturers to make sustainable products with renewable material, instead of oil, and to use less energy in the manufacturing process A recent Roundtable discussion hosted by the Industrial biotechnology Journal
and printed in its April edition features academic experts and executives from industrial biotechnology and consumer product companies discussing demand for sustainable products.
Visit Journal publisher Maryann Liebert at Booth 3617 in the BIO Exhibition. Consumers are looking for products that are safer,
Vice president of Global Sales and Applications for Dupont Industrial Biosciences. bout 80 percent of U s. consumers say they will buy green products
The $3. 5 trillion global chemicals market represents a significant opportunity for growth of industrial biotechnology that ultimately provides consumers a choice of safer, cleaner products f
Advances such as this show the promise of biotechnology to transform lives and enable patients who had relied previously on frequent,
and women at biotechnology companies across the world are working hard to advance every day. Read the full Wall street journal article here r
Industrial biotechnology continues to enable solutions to energy challenges and building a biobased economy is key to reducing dependence on foreign oil enhancing our nation economic and energy security.
Last week, the U s. Navy signed an agreement with biotech company Biodico to collaborate on developing advanced biofuels and bioenergy refineries throughout the globe for the U s. military.
The biopharmaceutical industry is an important contributor to U s. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion
As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors in the U s. It is becoming clear,
however, that the U s. can no longer take its leadership in biopharmaceuticals or other knowledge-based industries for granted.
many of which are targeted to the biopharmaceutical industry and related sectors. Despite the short-term costs associated with these investments,
As a result, more and more, the U s. is competing globally to maintain its leadership position in biopharmaceuticals.
For purposes of this study, entitled The Biopharmaceutical Research and development Enterprise: Growth Platform for Economies Around the World, Battelle examined policies
and programs being implemented to promote the bioscience sector in 18 countries and the European union (E u.).These countries were selected because of their interest in growing an innovation economy.
In addition, countries selected include a mix of developed countries with an existing biopharmaceutical presence (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, Sweden, the United kingdom UK,
and the E u. as a whole) and emerging countries that are targeting the biopharmaceutical sector (Brazil, Chile, China, Russia, Saudi arabia, Singapore, South africa, and South korea).
and capital, all of the countries examined are focusing on strategic components to grow their biopharmaceutical economy.
and programs to increase the economic footprint of the biopharmaceutical and related sectors in their own countries.
America innovative biopharmaceutical companies face increasing challenges, ranging from the cost and increased complexity of bringing new medicines to patients, the prospect of attracting
Just as other countries have drawn lessons from the growth of the U s. biopharmaceutical sector so too can the U s. learn from other countries that are strategically
Alicia Jackson, the deputy director of Darpa Biological Technologies Office In virginia, made comments alluding to the technology at a biotech conference on Monday. or the first time
Aurasense, Inc.,a biotechnology company that licensed the Nanoflare technology from the university, and EMD-Millipore, another biotech company, have commercialized Nanoflares.
There are now more than 1, 700 commercial forms of Nanoflares sold under the Smartflare name in more than 230 countries.
"The acquisition of NPS Pharma is a significant step in advancing Shire's strategy to become a leading biotechnology company, Shire CEO Flemming Ornskov, M d,
Amgen markets cinacalcet HCL as Sensipar in the U s. and as Mimpara in the EU;
and the Biotechnology industry Organization (BIO) ignaled support for sharing clinical trial data beyond recent industry norms,
Express Scriptsindependent Pharmacy & Therapeutics Committee concluded that Viekira Pak was at least clinically equivalent to two Gilead sciences drugs, Harvoni (ledipasvir and sofosbuvir) and Sovaldi (sofosbuvir.
Representatives of two other top-selling cancer drug developers, Celgene and Amgen, at deadline had responded not to GEN queries on indication pricing
according to Michael Egholm, president of Pall Biopharmaceuticals. The AWS technology works by applying acoustic forces across a flow channel to generate a three-dimensional standing wave.
but accelerating, a phenomenon that is reflected in the timing of biopharmaceutical product launches: Since the first biopharmaceutical drug Humulin was launched in 1982 to the beginning of this decade (between 1982 and 2009 27 year period),
there were 117 biopharmaceutical approvals. That an impressive number, but there have been 67 approvals between 2010 and 2014 four year period.
Roughly speaking, biopharmaceutical product launches increased from around 4 to nearly 17 approvals per year. Biopharmaceutical production is increasing not only through the introduction of novel therapeutics,
but also through the introduction of biosimilars or generic biopharmaceuticals, which can be manufactured by several companies.
The market for cell cultures is expected to grow rapidly alongside biopharmaceuticals and with significant evolution in culture technology.
Cell Line Trends Many biopharmaceuticals are produced by bacteria especially the species Escherichia coli and Bacillus subtilis. E coli has been studied in microbiology laboratories for many years
and was the first organism to have its entire genome mapped. It is inexpensive to cultivate,
it replicates quickly, and it serves as a good model organismhat is, it provides an example of how other similar life forms will behaveuch as how they grow
Bacterial culture is the workhorse of the biotechnology industry. Animal cells are much more fragile than yeast and bacterial cells.
The rising stakes and production levels of companies active in biopharmaceuticals have dictated improved reproducibility or consistency in product;
The biopharmaceutical industry shift away from animal-derived culture products is expected to continue, particularly given the ascension of mammalian cell lines in biopharmaceutical production.
Serum-free media is the more complex composition designed for universal use in culturing mammalian cell lines.
Working and Master Cell Banks Once a biopharmaceutical company obtains a beginning cell bank from a cell culture collection,
in particular single-use disposable production systems, are dramatically lowering building costs of biomanufacturing plants. In the near term
In the longer term, biomanufacturing expansion will extend into South america, Eastern europe, and Africa. Market Drivers An important driver of the cell culture market is the production of seasonal influenza vaccines,
Creating one of the batteries capable of delivering enough microwatts to run a biosensor in the field costs only five cents.
000 grant from the US National Science Foundation to create a self-powered system that can run the paper biosensor independently of other devices.
#Silk-based functional inks put biosensor data on your fingertips Although we've seen"bio-inks"that allow sensors to be drawn directly on a person's skin
and a Biotechnology and Biological sciences Research Council award, was published in the Science Translational Medicine journal in April.
A few years back while working as a postdoc in Vienna at the Institute of Molecular Biotechnology (IMBA
From the study abstract in journal Biosensors and Bioelectronics: Study in Biosensors and Bioelectronics: An organic electronic biomimetic neuron enables auto-regulated neuromodulationource:
Karolinska Institutet u
#To Be prescribed Soon: Implantable Drug Releasing Microchips Over the past few years wee covered Microchips Biotech, an MIT spin out company that developed an implantable technology to release drugs inside the body in a controlled manner.
It been almost a decade since the technology has had initial development, but now it may finally see clinical light of day.
added Hud, who is also director of the NSF-NASA Center for Chemical Evolution and associate director of the Parker H. Petit Institute of Bioengineering and Bioscience,
. a biotech company associated with Cedars-Sinai. The study was supported by NIH grants U01 CA151815, R01 CA136841, R01 CA188743,
-Legislation/Regulation/Funding/Policy MIPT physicists develop ultrasensitive nanomechanical biosensor June 9th, 2015nist's'nano-raspberries'could bear fruit in fuel cells June 9th, 2015filming the film:
2015mipt physicists develop ultrasensitive nanomechanical biosensor June 9th, 2015new composite material as CO2 sensor June 8th, 2015discoveries Designer electronics out of the printer:
2015newly-Developed Biosensor in Iran Detects Cocaine addiction June 23rd, 2015university of Tehran to Host 12th Int'l Confab on Membrane Science, Technology (MST2015) June 23rd,
2015newly-Developed Biosensor in Iran Detects Cocaine addiction June 23rd, 2015discoveries Nanometric sensor designed to detect herbicides can help diagnose multiple sclerosis June 23rd, 2015sweeping lasers snap together nanoscale geometric grids:
2015newly-Developed Biosensor in Iran Detects Cocaine addiction June 23rd, 2015iranian Scientists Design Nano Device to Detect Cyanogen Toxic Gas June 23rd,
2015newly-Developed Biosensor in Iran Detects Cocaine addiction June 23rd, 2015university of Tehran to Host 12th Int'l Confab on Membrane Science, Technology (MST2015) June 23rd,
2015newly-Developed Biosensor in Iran Detects Cocaine addiction June 23rd, 2015iranian Scientists Design Nano Device to Detect Cyanogen Toxic Gas June 23rd, 2015materials/Metamaterials n-tech Research Issues Report on Smart Coatings Market
and the Environment June 24th, 2015newly-Developed Biosensor in Iran Detects Cocaine addiction June 23rd, 2015iranian Scientists Design Nano Device to Detect Cyanogen Toxic Gas June 23rd,
#Biomanufacturing of Cds quantum dots: A bacterial method for the low-cost, environmentally-friendly synthesis of aqueous soluble quantum dot nanocrystals Abstract:
This biosynthetic approach provides a viable pathway to realize the promise of green biomanufacturing of these materials.
the biomanufacturing technique cuts that cost to about $1-$10 per gram. The substantial reduction in cost potentially enables large-scale production of QDS viable for use in commercial applications."
harnessing nature to create functional inorganic materials will provide a pathway to a future environmentally friendly biomanufacturing based economy.
2015newly-Developed Biosensor in Iran Detects Cocaine addiction June 23rd, 2015iranian Scientists Design Nano Device to Detect Cyanogen Toxic Gas June 23rd,
including landmark new student services centres-the Forum in Exeter and The Exchange on the Penryn Campus in Cornwall, together with world-class new facilities for Biosciences, the Business school and the Environment and Sustainability Institute.
#New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment Iranian researchers designed a biosensor with application in assessment of effectiveness of drugs on the stability of the four-strand structure of DNA to prevent the growth
Cost effective production method, quick response and high accuracy are among the advantages of the biosensor.
Gold nanoparticles have been used in the production of the biosensor. The four-strand structure of DNA plays an important role in the process of creation of cancerous cells and in the prohibition of a type of active enzyme in cancers.
it is very important to study the stability of this structure on biosensors and to create a simple method to investigate their interactions with a number of drugs and compounds.
The research team presented an effective method to detect the four-strand structure of DNA by using biosensors.
Electrochemical studies showed that the designed biosensor creates an appropriate environment for the evaluation of the drug abilities to stabilize the structure.
The most important advantage of this biosensor is the quick detection of drugs that are able to stabilize the four-strand structure of DNA
and gold nanoparticles was used as an appropriate bed for the production of biosensors to detect four-strand structure of DNA
2015new Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015discoveries Super graphene can help treat cancer July 10th,
Courtesy of SQZ Biotech) We wanted to remove an important barrier in using B cells as an antigen-presenting cell population,
Courtesy of SQZ Biotech) Through Cellsqueeze, the device platform originally developed at MIT, the researchers pass a suspension of B cells and target antigen through tiny, parallel channels etched on a chip.
After developing Cellsqueeze at MIT, Sharei co-founded SQZ Biotech in 2013 to further develop and commercialize the platform.
Meanwhile, SQZ Biotech aims to reduce the footprint of its device, which could potentially lower the time
"The ability to detect even smaller amounts of chemical and biological molecules could be helpful with biosensors that are used to detect cancer, Malaria, HIV and other illnesses."
Since the advent of biotechnology, researchers have modified bacteria to produce therapeutic drugs or antibiotics. In this novel study
#Physicists develop ultrasensitive nanomechanical biosensor Two young researchers working at the MIPT Laboratory of Nanooptics and Plasmonics,
The device, described in an article published in the journal Scientific Reports("All-nanophotonic NEMS biosensor on a chip"
-and nanomechanical biosensors for quite a while now and can say that no one has been able to introduce a simple and scalable technology for parallel monitoring that would be ready to use outside a laboratory.
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011